NICE Demands "Less Biased" Cost Data On Pradaxa For AF

 
• By The Pink Sheet Daily

Cost-watchdog NICE raises concerns over Boehringer's cost-effectiveness calculations for AF treatment Pradaxa.

More from Archive

More from Pink Sheet